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Aim: We estimated the cost-effectiveness of direct-acting
antiviral treatment (DAA) compared to triple therapy
(simeprevir, pegylated interferon-α [Peg-IFN], and ribavirin
[RBV]) (scenario 1), Peg-IFN + RBV (scenario 2), and non-antiviral
therapy (scenario 3).
Methods: Cost-effectiveness was evaluated as incremental
cost-effectiveness ratios (ICERs) using direct costs and indirect
costs, which included loss of wages during the patient’s lifetime
due to early death caused by viral hepatitis infection. Quality of
life (QOL) scores were determined by EQ-5D-3L questionnaire
survey on 200 HCV patients in Hiroshima.
Results: The QOL scores for chronic hepatitis, liver cirrhosis,
and hepatocellular carcinoma were estimated as 0.871, 0.774,
and 0.780, respectively. The follow-up period that the ICER of
scenario 1 becomes shortest (cost <¥6 million) was 25 years af-
ter treatment in men and women who started treatment at the
age of 20–60. In contrast, those of scenarios 2 and 3was 10 years
after treatment in patients who started treatment at age
<80 years. Based on the sensitivity analysis in scenario 1, the
most signiﬁcant factor affecting the value of ICER is the QOL
score after sustained virologic response (SVR), followed by the
SVR rate of DAA or follow-up period.
Conclusions: Direct-acting antiviral treatment was estimated
to be cost-effective from 10 to 25 years after treatment, depend-
ing on the SVR rate of the drugs and the age of onset of treat-
ment. In order to increase the cost-effectiveness of DAA
treatment, measures or effort to improve the QOL score of pa-
tients after SVR are necessary.
Key words: cost-effectiveness analysis, direct acting antiviral,
EQ-5D, hepatitis C virus, incremental cost-effectiveness ratio,
loss of productivity, Markov model, QALY
INTRODUCTION
THE WORLD HEALTH Organization has reported thatapproximately 2 billion people are infected with the
hepatitis B virus (HBV) and approximately 270 million
people are persistent HBV carriers. Furthermore, approxi-
mately 130–150 million people are persistently infected
with the hepatitis C virus (HCV), and >1 million deaths
each year are thought to be caused by liver diseases that
are associated with HBV and HCV infections.1 In Japan,
approximately 1.9–2.3 million people have persistent
HCV infections,2 and hepatitis-related diseases are wide-
spread. At the 69th World Health Assembly (May 2016),
the Global Strategy on Viral Hepatitis 2016–2020 was
unanimously adopted, with a goal of eliminating hepatitis
B and C by 2030. Themain targets are to reduce the annual
number of deaths by 65% and to increase the treatment
rate to 80% by 2030.3 Gilead Sciences Co. Ltd. supplies in-
expensive direct acting antiviral treatment (DAA) to low-
and middle-income countries, such as Cuba, Pakistan,
the Philippines, and Egypt, which increases local access
to chronic hepatitis C treatment.4
Japan has developed interventions to target HBV and
HCV carriers, which include prevention and control mea-
sures. Furthermore, hepatitis testing has been carried out
and promoted since the 1990s. Since the 2000s, each
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Japanese prefecture and district has implemented mea-
sures that are based on the “Basic Act on Hepatitis Mea-
sures”, which aim to increase the rates of examination,
diagnosis, and treatment using free-of-charge hepatitis
testing, reimbursement for some hepatitis-related medical
expenses, and regional hospitals that specialize in treating
liver disease. The countermeasure should focus on the ef-
fective treatment and follow-up after screening, and
Japan has shifted from screening to treatment.5 In addi-
tion, several highly effective, albeit expensive, direct-acting
antiviral (DAA) treatments have been developed to elimi-
nate HCV infection by directly affecting the enzymatic
activity of the HCV. Many clinical studies reported effec-
tiveness, safety, and impact on patients’ quality of life
(QOL) of DAA.6–9 However, concerns have been raised
regarding the cost-effectiveness of expensive medical
technologies, and their burden on Japan’s health insurance
system. Therefore, the present study examined the cost-
effectiveness of DAA and triple therapy (simeprevir
[SMV], pegylated interferon-α [Peg-IFN], and ribavirin
[RBV]).
The target population was deﬁned as HCV carriers in the
Hiroshima prefecture, which has had a screening system
since 1992 but still has a highmortality rate for hepatocel-
lular carcinoma (HCC).10 Hiroshima currently serves as a
model district for Japan, and has introduced advanced
countermeasures that include carrier surveillance and early
releases of new hepatitis treatments. Thus, we collected
data regarding the epidemiology of HCV infections, as well
as the carrier rate, rate of receiving antiviral therapy, and
disease states (HCC, liver cirrhosis [LC], and chronic hepa-
titis [CH]). Furthermore, QOL scores for patients in Hiro-
shima were estimated according to their disease state.
This cost-effectiveness study might help facilitate region-
speciﬁc hepatitis control measures.
METHODS
Ethical considerations
THIS STUDY’S PROTOCOL was approved by our insti-tutional ethics committee (Epi E-43). The main objec-
tives were explained to all participants and informed
consent was obtained after conﬁrming that the partici-
pants understood these objectives.
Patients and study design
The QOL scores were estimated using data from 212 pa-
tients who were treated as outpatients or inpatients at Hi-
roshima University Hospital (Hiroshima, Japan) between
August and September 2015. The required sample size
was calculated using the following formula,11 with abso-
lute accuracy of 0.03 and a QOL standard deviation of 0.1:
N ¼ 41:962 S2=W2:
In that equation, S denotes the QOL standard deviation,
W denotes the absolute accuracy, and 1.96 is the cut-off for
the upper 2.5% of the normal distribution. The required
sample size was calculated to be 129 (43 cases each for
CH, LC, and HCC), and we ultimately targeted 215 cases
based on an assumed response rate of 60%. The patients
were categorized according to their liver disease state, and
they provided information regarding their age and sex be-
fore self-administering the Japanese version of the EQ-5D-
3 L questionnaire (mobility, self-care, usual activities, pain,
and anxiety).12 The average health-related QOL scores
were calculated according to disease state based on the
conversion table.12
Model structure
TheMarkovmodel (Fig. 1) was used to simulate the cumu-
lative disease states (asymptomatic carriers [AC], CH, LC,
Death
SVR
HCCLCAC CH
Liver-related
or
Other cause
Figure 1 Markov model for the natural course of hepatitis C virus infection. The Markov model for this study consisted of six liver dis-
ease states, namely asymptomatic carrier (AC), chronic hepatitis (CH), liver cirrhosis (LC), hepatocellular carcinoma (HCC), sustained
virologic response (SVR), and death, and transition probabilities. The arrows indicate a transition between liver disease states over 1 year.
[Color ﬁgure can be viewed at wileyonlinelibrary.com]
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HCC, sustained virologic response [SVR], and death)
among HCV carriers with or without treatment. This
model included the SVR rates for DAA, triple therapy,
and Peg-IFN+RBV, the rates of receiving antiviral therapy,
the mortality rate for all causes, and annual transition
probability matrixes.13 Three treatment strategies were as-
sumed in scenario 1 (DAA vs. triple therapy), scenario 2
(DAA vs. Peg-IFN+RBV) and scenario 3 (DAA vs. non-
antiviral treatment). The following assumptions were
made: (i) the six liver disease states (AC, CH, LC, HCC,
SVR, and death) are mutually exclusive and collectively ex-
haustive; (ii) the rates of visiting a medical institution are
100% for the ﬁrst time, 65% for the next time for CH,
80% for LC, and 95% for HCC (Table 1); (iii) only CH is
eligible for anti-HCV treatment; (iv) the targeted age range
for anti-HCV treatment is 20–90 years; (v) the rate of re-
ceiving antiviral therapy is 65% for CH (Table 1); (vi) if
patients with CH do not respond to antiviral treatment
(non-SVR), the transition from CH to AC is zero; (vii)
the SVR rate for each age group is constant (0% for non-
antiviral treatment in scenario 3, 45% for Peg-IFN+RBV
in scenario 2, 88.6% for triple therapy in scenario 1, and
100% for DAA);14 (viii) the model is limited by an age
of 100 years; (ix) the annual discount rates for costs and
quality-adjusted life years (QALY) are 2%.15
Model development
Model population
The numbers of untreated patients in Hiroshima prefec-
ture were estimated using the following formula (Table 1):
UPijd ¼ PijHCVij0:7LDSijd:
In that equation, i denotes sex (1 formen, 2 for women),
j denotes age (1 for 20–24 years, 2 for 25–29 years, 17 for
≥100 years), d denotes the disease state at the start of
follow-up (1 for AC, 2 for CH, 3 for LC), UPijd denotes
the estimated number of untreated HCV carriers in Hiro-
shima, Pij denotes the population of Hiroshima,
16 HCVij
denotes the anti-HCV positivity rate in Hiroshima,17 0.7
is the proportion of HCV carriers among anti-HCV positive
individuals,17 and LDSijd denotes the proportion of each
liver disease state (e.g., LDS111 is the proportion of AC
among male 20–24-year-old HCV carriers).18
Base setting value
In the base setting value, treatment is started at the age of
50 years, the discount rate is 2%, the rate of receiving anti-
viral therapy is 65%,10 the SVR rate after DAA treatment is
Table 1 Number of hepatitis C virus (HCV) carriers in Hiroshima prefecture, Japan
Age,
years
Population of Hiroshima (2010)† Estimated no. of HCV carriers‡ Diagnosed in men§ Diagnosed in women§
Total Men Women Total Men Women AC CH LC HCC AC CH LC HCC
20–24 137098 69684 67414 120 54 66 19 35 0 0 44 22 0 0
25–29 153042 77217 75825 134 59 75 21 38 0 0 50 25 0 0
30–34 178636 89808 88828 263 126 137 45 81 0 0 91 46 0 0
35–39 216329 108 188 108141 318 152 166 54 98 0 0 111 55 0 0
40–44 184012 91510 92502 972 525 447 183 338 4 0 260 187 0 0
45–49 168328 83426 84902 888 478 410 167 308 3 0 239 171 0 0
50–54 167126 82409 84717 1501 813 688 329 477 7 0 360 325 3 0
55–59 191535 94642 96893 1719 933 786 378 547 8 0 411 371 4 0
60–64 232762 113 986 118776 2931 1444 1487 505 867 36 36 766 699 22 0
65–69 189386 90135 99251 2386 1143 1243 400 685 29 29 640 584 19 0
70–74 151666 69745 81921 3595 1685 1910 590 1011 42 42 983 898 29 0
75–79 133626 56550 77076 3161 1365 1796 478 819 34 34 925 844 27 0
80–84 103132 39509 63623 2437 954 1483 334 572 24 24 764 697 22 0
85–89 61669 19156 42513 1455 464 991 162 278 12 12 510 466 15 0
90–94 27347 6735 20612 643 163 480 57 98 4 4 247 226 7 0
95–99 8439 1649 6790 198 40 158 14 24 1 1 82 74 2 0
≥100 1395 190 1205 32 5 27 2 3 0 0 14 13 0 0
Total 22753 10403 12350 3738 6279 204 182 6497 5703 150 0
†Vital Statistics in Japan (2010), Ministry of Health, Labour and Welfeare.
‡Tanaka J et al. Intervirology 2004; 47: 32–42.
§Mizui M et al. Hepatol Res 2007; 37: 994–1001.
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100%,19 triple therapy is 88.6% and Peg-IFN+RBV is 45%,
the QOL score after SVR is 1.000, and the drug costs are set
according to the National Drug Tariff (April 2016).
Mortality rate
The annual mortality rates were assumed to be 0.225 for
HCC20 and 0.061 for LC.21 Mortality rates for all causes
of death in Hiroshima prefecture were calculated accord-
ing to 2010 mortality data (Table 2).22
Direct costs
Direct costs include the cost of treatment and drugs. The
total costs23 of HCV antiviral treatment for CH were esti-
mated to be ¥4603000 for DAA (12 weeks) and
¥1837000 for triple therapy (24 weeks for Peg-IFN+RBV,
and 12 weeks for SMV), ¥1470000 for Peg-IFN+RBV
(48 weeks) based on the National Drug Tariff (April
2016). The total costs of non-antiviral treatment for CH,
LC, and HCC were estimated using an insurance and clin-
ical practice survey that was published by the Ministry of
Health, Labour, and Welfare in June 2011.24 The numbers
of CH, LC, and HCC cases were calculated based on the
2014 Patient Survey in Japan,25 using codes for viral hepa-
titis (International Classiﬁcation of Diseases and Related
Health Problems, 10th revision [ICD-10] codes: B15–
B19), liver cirrhosis except alcoholic cirrhosis (ICD-10:
K74.3–K74.6), and malignant neoplasm of the liver and
intrahepatic bile duct (ICD-10: C22). Based on these
factors, the per-capita medical costs were estimated to be
¥540000 for CH, ¥527000 for LC, and ¥2160000 for
HCC. These medical costs included consultations, treat-
ment, radiographic imaging, pathological testing, surgery,
hospital charges, and nutritional support for inpatients
(Table 2).
Indirect costs
Indirect costs include loss of productivity, which was de-
ﬁned as the “loss of wages during the patient’s lifetime
due to early death caused by viral hepatitis infection,”
and was estimated using the human capital valuation
method:15
LD ¼ ∑
DþLED1
i¼D
EiWi
1þ rð Þi1
In that equation,D denotes age at death, LD denotes the
loss of wages during the patient’s lifetime due to early
death at age D, LED denotes life expectancy at age D, i
denotes the index of age, r denotes the discount rate
(2%)15 and Ei and Wi denote the employment rate and
annual wages at age i, respectively. The employment rate
was based on the 2015 Labour Force Survey26 the annual
income was based on the 2015 Basic Survey on Wage
Structure.27 Life expectancy was based on the 2010 Life
Table.22
Table 2 Parameters and costs of each stage of anti-hepatitis C
virus treatments in patients with chronic liver disease in
Hiroshima prefecture, Japan
Item Value Ref.
QOL scores AC 1.000
SVR 1.000
CH 0.871
LC 0.774
HCC 0.780
Direct costs, ¥1000 DAA 4603 23†
Triple therapy 1837 23‡
Peg-IFN+RBV 1470 23§
CH 540 24
LC 527 24
HCC 2610 24
Indirect costs Loss of wages during
the patient’s lifetime
due to early death
caused by viral hepatitis
infection
¶
Rate of receiving
antiviral therapy
65% 10
Rate of visits to
medical institutions
CH (for the
ﬁrst time)
100%
CH (for the
second time)
65%
LC 80%
HCC 95%
Rate of SVR DAA 100%
Triple therapy 88.6%
Peg-IFN+RBV 45.0%
Death rate LC 0.061 21
HCC 0.225 20
Others Death rate in
Hiroshima
22
†Ledipasvir + sofosbuvir [LDV + SOF] for 12 weeks.
‡Pegylated interferon + ribavirin [Peg-IFN + RBV] for 24 weeks
+ simeprevir [SMV] for 12 weeks.
§Peg-IFN+RBV for 48 weeks.
¶Loss by early death = Σ i = D
D + LE – 1{(operation rate in age i * annual
wage in age i)} / (1 + r)i 1
AC, asymptomatic carrier; CH, chronic hepatitis; DAA, direct-acting
antiviral; HCC, hepatocellular carcinoma; LC, liver cirrhosis; QOL,
quality of life; SVR, sustained virologic response.
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Model outcomes
The total costs and QALYs for DAA, triple therapy
(scenario 1), Peg-IFN+RBV (scenario 2), and non-antiviral
treatment (scenario 3) were used to calculate the
incremental cost-effectiveness ratios (ICERs), based on
the guidelines for Economic Evaluation of Health Care
Technology in Japan,15 to compare the treatments for
5-year increments ranging from 5 years to 50 years after
starting treatment:
ICER ¼ Total costsDAA  Total coststriple therapy or PegIRNþRBV or nonantiviral treatment
QALYsDAA  QALYstriple therapy or PegIFNþRBV or nonantiviral treatment
In our study, the cut-off ICER value for determining cost-
effectiveness was set to ¥5 million or ¥6 million.28
Sensitivity analysis
In scenario 1, sensitivity analyses were carried out to assess
the inﬂuence of speciﬁc input parameters on the cost-
effectiveness results: patient age (±10 years), discounting
(±2%), patient sex (male/female), follow-up period
(±10 years), HCC treatment cost (±20%), DAA cost
(±20% based on the 2015 National Drug Tariff), DAA
SVR (100–95%), QOL scores after SVR (1.000–0.871),
and the rate of receiving DAA therapy (65–85%).
RESULTS
Quality of life scores
AMONG THE 212 eligible patients, 200 patients(94.3%) responded to the QOL questionnaires
(105 men [52.5%] and 95 women [47.5%]). The largest
age subgroups were 60–69 years old (65 patients, 32.5%)
and 70–79 years old (62 patients, 31.0%). The disease
states were CH for 108 patients (54.0%), LC for 24
patients (12.0%), and HCC for 68 patients (34.0%)
(Table 3). The results from the EQ-5D-3L questionnaires
are summarized in Table 3. The average QOL scores for
patients in Hiroshima prefecture were estimated to be
0.871 for CH, 0.774 for LC, and 0.780 for HCC
(Table 4).
Table 3 Number of respondents to each dimension of the EQ-5D-3L questionnaire among 200 hepatitis C virus (HCV) patients in
Hiroshima prefecture, Japan
EQ-5D dimension
HCV disease stage
CH Comp-LC Decomp-LC HCC
n =108 n= 20 n =4 n=68
Mobility
No problem 93 (86.1) 14 (70.0) 1 (25.0) 42 (61.8)
Some problems 15 (13.9) 5 (25.0) 3 (75.0) 26 (38.2)
Extreme problems 0 (0.0) 1 (5.0) 0 (0.0) 0 (0.0)
Self-care
No problem 105 (97.2) 19 (95.0) 2 (50.0) 57 (83.8))
Some problems 2 (1.9) 1 (5.0) 2 (50.0) 9 (13.2)
Extreme problems 1 (0.9) 0 (0.0) 0 (0.0) 2 (3.0)
Usual activities
No problem 90 (83.3) 11 (55.0) 1 (25.0) 40 (58.8)
Some problems 17 (15.7) 9 (45.0) 3 (75.0) 24 (35.3)
Extreme problems 1 (1.0) 0 (0.0) 0 (0.0) 4 (5.9)
Pain/discomfort
No pain/discomfort 80 (74.1) 12 (60.0) 1 (25.0) 38 (55.9)
Moderate pain/discomfort 23 (21.3) 8 (40.0) 2 (50.0) 29 (42.6)
Extreme pain/discomfort 5 (4.6) 0 (0.0) 1 (25.0) 1 (5.9)
Anxiety/depression
No anxiety/depression 85 (78.7) 16 (80.0) 3 (75.0) 50 (73.5)
Moderate anxiety/depression 20 (18.5) 4 (20.0) 0 (0.0) 17 (25.0)
Extreme anxiety/depression 3 (2.8) 0 (0.0) 1 (25.0) 1 (1.5)
Data are shown as n (%).
CH, chronic hepatitis; Comp-LC, compensated liver cirrhosis; Decomp-LC, decompensated liver cirrhosis; HCC, hepatocellular carcinoma.
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Cost-effectiveness analyses
Incremental cost-effectiveness ratios in the base
setting value
In the base setting value, treatment is started at the age of
50 years. In scenario 1 (DAA vs. triple therapy), the ICERs
for direct costs (treatment and drug costs) after 25 years of
follow-up (i.e., ≥75 years old) were estimated according
to disease state (Table 5) and were ¥5671000/QALY for
men and ¥6075000/QALY for women. The ICERs for
both direct and indirect costs (loss of productivity) after
25 years follow-up were ¥5018000/QALY for men and
¥5712000/QALY for women (Table 6). In scenario 2
(DAA vs. Peg-IFN+RBV) and scenario 3 (DAA vs. non-
antiviral treatment), the ICERs for direct costs after 10 years
of follow-up were ¥2863000/QALY for men and
¥3467000/QALY for women, and ¥1715000/QALY for
men and ¥2203000/QALY for women, respectively.
Incremental cost-effectiveness ratios according to sex
and age at the start of treatment
In scenario 1, ICERs for direct costs according to sex and
age at the start of treatment were estimated (Fig. 2a). In
scenario 1, the case of DAA treatment started at age of
50 years old for men (¥5671000/QALY) and 60 years
old for women (¥5959000/QALY); the ICER values
reach cost-effectiveness within shortest period at 25 years.
In men who started treatment at the age of 20 years, the
follow-up period that the ICER <¥6 million was
35 years after treatment (¥5124000/QALY), compared
to 30 years after treatment in men who started
Table 4 Quality of life (QOL) scores among HCV patients in
Hiroshima prefecture, Japan, with chronic hepatitis (CH), liver
cirrhosis (LC), or hepatocellular carcinoma (HCC)
Condition of liver
disease
No. of
patients
QOL
scores 95% CI
CH 108 0.871 (0.824–0.917)
LC 24 0.774 (0.649–0.900)
Comp-LC 20 0.824 (0.718–0.930)
Decomp-LC 4 0.524 (0.000–1.00)
HCC 68 0.780 (0.723–0.837)
HCC 14 0.750 (0.619–0.881)
HCC – early 23 0.838 (0.759–0.917)
HCC – intermediate 15 0.786 (0.681–0.891)
HCC – advanced 16 0.716 (0.540–0.892)
CI, conﬁdence interval; Comp-, compensated; Decomp-,
decompensated.
Table 5 Incremental cost-effectiveness ratios (ICER) of anti-hepatitis C virus treatments among patients with chronic liver disease in
Hiroshima prefecture, Japan, based on direct costs
Gender
Follow-up
period, years
DAA Triple therapy
ΔCost ΔQALY
ICER,
¥1000
/QALY
Total direct
costs, ¥1000 QALYs
Total direct
costs, ¥1000 QALYs
Male 15 4752 748 20795 2604 635 20611 2148 113 184 11675
20 5002 159 25728 2944 215 25460 2057 944 268 7679
25 5190 272 29657 3210 960 29308 1979 312 349 5671
30 5324 428 32546 3406 851 32125 1917 577 421 4555
35 5412 403 34400 3537 064 33926 1875 339 474 3956
40 5463 135 35362 3611 630 34858 1851 505 504 3674
45 5487 622 35726 3646 502 35210 1841 120 516 3568
50 5494 229 35800 3655 621 35281 1838 608 519 3543
Female 15 3785 994 18159 1964 920 18023 1821 074 136 13390
20 4086 326 22753 2300 698 22547 1785 628 206 8668
25 4320 535 26637 2595 171 26353 1725 364 284 6075
30 4500 572 29790 2838 717 29428 1661 855 362 4591
35 4635 424 32171 3028 487 31738 1606 937 433 3711
40 4731 779 33736 3165 130 33251 1566 649 485 3230
45 4795 454 34535 3253 182 34023 1542 272 512 3012
50 4817 268 34748 3282 634 34229 1534 634 519 2957
ΔCost = Total direct costs DAA total direct costs triple therapy
ΔQALY =QALYs DAAQALYs triple therapy
In the base setting value, treatment is started at the age of 50 years, the rate of receiving antiviral therapy is 65%, and the discount rate is 2%.
DAA, direct-acting antiviral; QALY, quality-adjusted life years; Triple therapy, simeprevir, pegylated interferon-α, and ribavirin.
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treatment at the age of 30 years (¥5587000/QALY),
40 years (¥4799000/QALY), or 60 years (¥5651000/
QALY).
Inwomenwho started treatment at the age of 20, the fol-
low-up period that the ICER becomes <¥6 million was
40 years after treatment (¥5041000/QALY), compared
to 30 years after treatment in those who started treatment
at the age of 40 years (¥5619000/QALY) or 50 years
(¥4591000/QALY).
In both men and women who started treatment at
the age of ≥80 years, the ICER values did not reach
cost-effectiveness (<¥6 million) before 100 years of age;
however, the ICER values decreased slightly.
In scenario 2, the follow-up period after treatment
that the ICER becomes <¥6 million was 10 years for
men and women who started treatment at the age of
under 80 (Fig. 2b). That is, in men who started treatment
at the age of 20 years (¥3357000/QALY), 30 years
(¥3369000/QALY), 40 years (¥3118000/QALY), 50 years
(¥2863000/QALY), 60 years (¥2403000/QALY), 70 years
(¥2885000/QALY), or 80 years (¥4493000/QALY), the
follow-up time to an ICER of <¥6 million was 10 years
after treatment.
In women who started treatment at the age of 20 years
(¥3997000/QALY), 30 years (¥3884000/QALY), 40 years
(¥3802000/QALY), 50 years (¥3467000/QALY),
60 years (¥3064000/QALY), 70 years (¥3314000/
QALY), or 80 years (¥4305000/QALY), the follow-up
time to an ICER of <¥6 million was 10 years after
treatment.
In scenario 3, the follow-up period after treatment that
the ICER becomes <¥6 million was also 10 years for
men and women who started treatment at age <80 years.
Although in patients who started treatment at the age of
90 years the ICER values did not reach cost-effectiveness
(<¥6 million), the value decreased remarkably (Fig. 2c).
Sensitivity analyses
The results of the sensitivity analyses are shown in Figure 3
and Table 7. In the case of changing QOL score after SVR
from 1.0 (base setting value; base) to 0.871, the ICERs in
men were ¥4555000 (base)–11552000/QALY and the
ICERs in women were ¥4591000 (base)–12130000/
QALY. In the case of changing the SVR rate of DAA treat-
ment from 100% (base) to 95%, the ICERs in men were
¥4555000 (base)–9502000/QALY and the ICERs in
Table 6 Incremental cost-effectiveness ratios (ICERs) of anti-hepatitis C virus treatments among patients with chronic liver disease in
Hiroshima prefecture, Japan, based on direct and indirect costs
Gender
Follow-up
period, years
DAA Triple therapy
ΔCost ΔQALY
ICER,
¥1000
/QALY
Total (direct + indirect)
costs, ¥1000 QALYs
Total (direct + indirect)
costs, ¥1000 QALYs
Male 15 6098843 20795 4134 893 20611 1963 950 184 10674
20 6482333 25728 4638 818 25460 1843 515 268 6879
25 6726978 29657 4975 742 29308 1751 236 349 5018
30 6885152 32546 5202 079 32125 1683 073 421 3998
35 6977282 34400 5338 396 33926 1638 886 474 3458
40 7017941 35362 5401 593 34858 1616 348 504 3207
45 7022646 35726 5413 119 35210 1609 527 516 3119
50 6377164 35800 4672 814 35281 1704 350 519 3284
Female 15 4163061 18159 2402 963 18023 1760 098 136 12942
20 4576630 22753 2877 379 22547 1,699 251 206 8249
25 4882626 26637 3260 462 26353 1622 164 284 5712
30 5106768 29790 3558 784 29428 1547 984 362 4276
35 5264248 32171 3776 858 31738 1487,390 433 3435
40 5369764 33736 3925 156 33251 1444,608 485 2979
45 5433145 34535 4013 165 34023 1419 980 512 2773
50 5156710 34748 3685 173 34229 1471 537 519 2835
ΔCost = Total (direct + indirect) costs DAA total (direct + indirect) costs triple therapy
ΔQALY=QALYs DAA - QALYs triple therapy
In the base setting value, treatment is started at the age of 50 years, the rate of receiving antiviral therapy is 65%, the discount rate is 2%, including
direct and indirect costs.
DAA, direct-acting antiviral; QALY, quality-adjusted life years; Triple therapy, simeprevir, pegylated interferon-α, and ribavirin.
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women were ¥4591000 (base)–9582000/QALY. In the
case of changing the DAA costs from 20% (¥3682000)
to +20% (¥5524000), the ICERs in men were
¥2435000–6675000/QALY and the ICERs in women
were ¥2468000–6713000/QALY. In the case of changing
the follow-up period from 20 years to 40 years, the ICERs
in men were ¥7679000–3674000/QALY and the ICERs
in women were ¥8668000–3230000/QALY. In the case
of changing the rate of receiving DAA therapy from 65%
(base) to 85%, the ICERs in men were ¥4555000
(base)–1865000/QALY and the ICERs in women were
¥4591000 (base)–1858000/QALY.
DISCUSSION
DECLINING BIRTH RATES and prolonged lifespanshave been associated with remarkable increases in
national health-care costs, as the introduction of expensive
but innovative drugs can create drastic changes in medical
care. These treatments must be evaluated for safety, effec-
tiveness, and cost-effectiveness, which highlights the need
for new criteria that incorporate direct and indirect costs,
as well as the resulting changes in QOL.29 Other countries
have developed specialized cost-effectiveness evaluations
for depression30 and cancer treatments31 and a Japanese
cost-effectiveness subcommittee was established in 2012.
One pilot study in Japan was completed in 2016, and a
full-scale study is planned for 2018.32
There are several recently published reports that are re-
lated to our study, that is, cost-effectiveness of DAA.33,34
McEwan et al. showed the cost-effectiveness of DAA treat-
ment (daclatasvir + asunaprevir) compared to simeprevir
+ Peg-IFN+RBV or telaprevir + Peg-IFN+RBV using
transition probabilities through all ages, based on other
published reports.33 Tanaka et al. analyzed the cost-
effectiveness of antiviral treatment for HCV patients based
(a) (b) (c)
Figure 2 Incremental cost-effectiveness ratios (ICERs) of anti-hepatitis C virus treatments among patients with chronic liver disease in
Hiroshima prefecture, Japan, classiﬁed by treatment starting age, sex, and follow-up period. The assumptions were a 65% rate of receiv-
ing antiviral therapy and a 2.0% discount rate. The sustained virologic response rates were 88.6% for triple therapy (simeprevir +
pegylated interferon-α [Peg-IFNα], and ribavirin [RBV]) in scenario 1, 45% for Peg-IFN+RBV in scenario 2, 0% for non-antiviral treat-
ment in scenario 3, and 100% for direct-acting antiviral (DAA) treatment. (a) Scenario 1, DAA vs. triple therapy. (b) Scenario 2, DAA vs.
Peg-IFN+RBV. (c) Scenario 3, DAA vs. non-antiviral treatment. [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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4,555 
4,555 
2,435 
3,674 
3,085 
1,865 
4,555 
4,481 
11,552 
9,502 
6,675 
7,679 
6,364 
4,555 
5,651 
4,629 
QOL scores(SVR:1.0-0.871)
DAA SVR(100-95%)
DAA costs(±20%)
Follow-up period (20-40years)
Discount rate(0-4%)
Rate of receiving DAA therapy
(65 - 85%)
Age(40-60years)
HCC treatment costs(±20%)
4,591 
3,230 
4,591 
2,468 
3,149 
1,858 
4,591 
4,542 
12,130 
8,668 
9,582 
6,713 
6,349 
4,591 
5,619 
4,640 
QOL scores(SVR:1.0-0.871)
Follow-up period(20-40years)
DAA SVR(100-95%)
DAA costs(±20%)
Discount rate(0-4%)
Rate of receiving DAA therapy
(65 - 85%)
Age(40-60years)
HCC treatment costs(±20%)
ICER(thousand ye/QALY)ICER(thousand yen/QALY)
(b) Women(a) Men
Figure 3 Univariate sensitivity analyses of the base setting value of incremental cost-effectiveness ratios (ICERs) of antihepatitis C virus
treatments among patients with chronic liver disease in Hiroshima prefecture, Japan. Bars indicate the change in the ICERs for each pa-
rameter. DAA, direct-acting antiviral; HCC, hepatocellular carcinoma; QALY, quality-adjusted life years; QOL, quality of life; SVR,
sustained virologic response. [Color ﬁgure can be viewed at wileyonlinelibrary.com]
Table 7 Univariate sensitivity analysis of base-case
Scenario
DAA (LDV+ SOF) vs. triple therapy (Peg-IFN+RBV+ SMV)
Men Women
Incremental
cost, ¥1000
Incremental
QALY
ICER, ¥1000
/QALY
Incremental
cost, ¥1000
Incremental
QALY
ICER, ¥1000
/QALY
Direct cost Base case† 1917 577 421 4555 1661 855 362 4591
Age (+10 years) 2 622 153 464 5651 3066 868 625 4907
Age (10 years) 1 151 718 240 4799 949 663 169 5619
Discount rate (0%) 1795 368 582 3085 1618 349 514 3149
Discount rate (4%) 1991 965 313 6364 1676 073 264 6349
Follow-up period (+10 years) 1 851 505 504 3674 1566 649 485 3230
Follow-up period (10 years) 2 057 944 268 7679 1785 628 206 8668
HCC treatment costs (+20%) 1886 459 421 4481 1644 106 362 4542
HCC treatment costs (20%) 1948 695 421 4629 1679 603 362 4640
DAA costs (+20%) 2809 980 421 6675 2430 284 362 6713
DAA costs (20%) 1025 174 421 2435 893 425 362 2468
DAA costs (2015 National
Drug Tariff)
3 580 296 421 8504 3093 587 362 8546
DAA SVR (95%) 2252 024 237 9502 1945 160 203 9582
QOL scores for SVR (0.871) 1 917 577 166 11552 1661 855 137 12130
Receival rate of anti-virus
therapy (+20%)
2867 682 1538 1865 2495 492 1343 1858
Direct +
indirect cost
Base case† 1 683073 421 3998 1547 984 362 4276
HCC death rate (+5%) 1,698 504 431 3941 1561 108 368 4242
HCC death rate (5%) 1659 733 407 4078 1529 987 355 4310
†In the base treatment scenario, age at the start of treatment is 50 years, follow-up period is 30 years, discount rate is 2%, the receival rate of an-
tiviral therapy is 65%, direct-acting antiviral (DAA) sustained virologic response (SVR) is 100%, quality of life (QOL) scores for SVR is 1.00, and
the drug cost is according to the National Drug Tariff (April 2016).
HCC, hepatocellular carcinoma; ICER, incremental cost-effectiveness ratio; Peg-IFNα, pegylated interferon-α; LDV, ledipasvir; QALY, quality-ad-
justed life years; RBV, ribavirin; SMV, simeprevir; SOF, sofosbuvir.
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on disability-adjusted life-years as an index of cost-
effectiveness, and it was concluded that the elimination
model promoting DAA treatment is the most cost-effective
as DAA treatment can reduce the cost per year of disability
to the lowest level.34
In this study, we could estimate ICERs as an index of
cost-effectiveness classiﬁed by sex and age groups applying
transition probabilities calculated from a Japanese cohort
study. We were also able to report, for the ﬁrst time, the
cost-effectiveness of DAA treatment by age of starting treat-
ment and by follow-up period after SVR. Furthermore, this
study pointed out the importance of evaluating the cost-
effectiveness of DAA treatment according to different med-
ical subsidies systems, hepatitis virus examination rates,
medical institution receiving rates, and HCV carrier rates
for each administrative district.
The present study estimated QOL scores among HCV
carriers speciﬁcally residing in Hiroshima prefecture using
the EQ-5D-3L questionnaire. Because every prefecture has
its own parameters, such as the QOL scores, estimated
number of HCV carriers in 2010, the rates of receiving an-
tiviral treatments, and the mortality rate, the ICER value
might also vary in every prefecture. As the reference model
for other prefectures, using prefecture-speciﬁc parameters,
we simulated age- and sex-speciﬁc ICER values in Hiro-
shima prefecture for DAA treatment compared to triple
therapy, Peg-IFN+RBV, or non-antiviral treatment.
The EQ-5D tool was developed by the EuroQol Group,
which was established in 1987, and has been translated
into >170 languages as the international standard for cal-
culating QALYs.35 The Japanese version of EQ-5D-3L was
released in 1997 and has been certiﬁed by the EuroQol
Group.36 However, the QOL scores using for cost-
effectiveness analyses have typically been calculated using
the EQ-5D tool, which assigns a score of 0 to death and a
score of 1 to healthy status.37 We used ICERs to evaluate
cost-effectiveness, which reﬂect the cost to achieve 1 QALY.
According to Shiroiwa et al.,28,38 the willingness-to-pay
threshold is ¥5–6million/QALY,whichhas been considered
as a reference of cut-off value for determination of cost-
effectiveness in Japan; this value was applied in this study.
The direct costs showed a decreasing trend for ICERs in
both sexes and every age group after treatment, although
men tended to have lower ICERs than women during the
early follow-up period after treatment. In scenario 1, that
is, compared to triple therapy, DAA treatment was cost-
effective for patients who started treatment at the age of
20–60 years, followed by 25–35 years after treatment.
However, DAA treatment was not relatively cost-effective
if DAA treatmentwas started at>70 years, even for survival
to age 100 years, which is likely related to the high
all-cause mortality rate. In this analysis, we assumed the
discount rate was 2%, that is, values of QALY and costs
in future were discounted by length of follow-up period.
The discount rate (2%) is used to calculate future value
discounted to the present. For example, ¥1 million after
10 years will be ¥836000 for the current value, and QALY
1 after 10 years will be 0.84 of the current value. QALY is
associated with the progress of hepatitis. In younger gener-
ation, the period until liver pathology progresses to LC/
HCC is longer than elderly. The treatment costs are same
for each generations. However due to the adaptation of
the discount rates, the QALY in the distant future becomes
lower as a current value. Therefore in younger generation
ΔQALY estimated lower than the elderly generation. For
this reason, if the discount rate is 0%, DAA treatment is
more cost-effective in scenario 1 after 25 years of treatment
for all generations who started treatment at age<70 years.
Furthermore, in scenarios 2 or 3, that is, compared to
Peg-IFN+RBV or non-antiviral treatment, DAA treatment
was estimated to be cost-effective after 10 years of
treatment in all age patients, excluding those who started
treatment at the age of 90 years. Even in patients who
started treatment at the age of 90 years, the ICER values
decreased remarkably after 10 years of treatment, but did
not reach <¥6 million. In our study, elderly people in
Japan have little or no income, and there is no difference
in indirect costs between treated patients with SVR and un-
treated patients. From our analysis, it means indirect costs
may not signiﬁcantly affect the ICER in some populations
where most HCV patients are elderly.
The Ministry of Health, Labour, and Welfare guide-
lines15 indicate that public nursing costs and indirect costs
(loss of productivity) should not be included in the pre-
liminary evaluation of cost-effectiveness, although they
should be considered in subsequent evaluations. This
may be because loss of productivity among HCV carriers
is generally related to “loss of incomes/wages due to
HCV-related early death” and “loss due to a decline in
the job performance” (i.e., absenteeism).39 Thus, the
present study estimated loss of productivity due to “a loss
of income caused by early death due to HCV infection,”
but excluded indirect costs due to absenteeism in order
to prevent double counting of absenteeism.40
In scenario 1 (DAA vs. triple therapy), based on the sen-
sitivity analysis, QOL scores after SVR had signiﬁcantly
greater effects on the ICER values than the receiving rate
of DAA treatment or SVR rate of DAA treatment. It indi-
cates that, in order to increase cost-effectiveness of DAA
treatment, measures or effort to improve the QOL score
of patients after SVR are important. Therefore, in order to
avoid the risk of carcinogenesis after SVR, which is
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reported by some clinical research, it is considered that
patients after SVR need to visit medical institutions period-
ically. It is important to explain the follow-up system
currently being maintained in each prefecture to patients
and obtain their understanding. By encouraging patients
to register in this system, regular check-ups will be possi-
ble. Providing information on health promotion (e.g., ex-
ercise and nutrition) using the system to registrants might
assist in maintaining and improving their QOL.
Because of their relatively short life expectancy, DAA
treatment did not show cost-effectiveness for patients who
started treatment at the age >80 years. However, in Japan,
the HCV carrier rate among older people is higher than that
among young people;41 for example, approximately 50%
of HCV carriers in Hiroshima were over the age of 80 years
(Table 2). Furthermore, the new HCV infection rate in
Japan is very low (0.7/100000 person-years [95% conﬁ-
dence interval, 0.6–0.9]).13 However, the cause of HCV
infection is unclear in up to 60% of new hepatitis C cases,
and the incidence of HCV infection in women is highest
among the age groups 50–60 years and 20–30 years.13
Therefore, DAA treatment for HCV carriers aged >60 years
might still be effective for preventing new HCV infections.
This study has several limitations. First, the incidence of
HCC after SVR was assumed to be zero in this study, but
there are some reported cases that have developed HCC
after starting DAA treatment, which might have increased
the ICER estimates. Second, method to determine the
cut-off value of ICER for determining cost-effectiveness is
not unique.42 For example, if we apply the cut-off based
on three times of the gross domestic product per capita,
cut-off value becomes ¥12573000,43–45 instead of
willingness-to-pay, DAA treatment would be evaluated as
more cost-effective. Finally, we should consider the high
SVR rate as a beneﬁts of DAA treatment, which may help
prevent new infections.46
Although the cost of DAA treatment remains high in
developed countries, DAA was cost-effective compared to
triple therapy, PEG-IFN+RBV, and non-antiviral treat-
ment, even for elderly patients.
In terms of HCV infection prevention, DAA treatment
should be recommended to elderly patients. To improve
the cost-effectiveness of DAA treatment, strategies to in-
crease the QOL scores of HCV patients after SVR are
important.
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